 |
|
|
Important Notice: The Forum does not endorse any medical
product or therapy. ALL medications and supplements
should be taken ONLY under the supervision of a physician,
due to the possibility of side-effects, drug interactions,
etc.
|
Drug:
|
ABT089
|
|
Clinical Trial ID:
|
NCT00391729
|
|
Mode of action:
|
nAChR agonist
|
|
Phase:
|
Phase 2
|
|
Company:
|
Abbott
|
|
Note:
|
Cognitive enhancer add-on; now in development only for ADHD
|
Rueter LE, Anderson DJ, Briggs CA, Donnelly-Roberts DL,
Gintant GA, Gopalakrishnan M, Lin NH, Osinski MA, Reinhart
GA, Buckley MJ, Martin RL, McDermott JS, Preusser LC,
Seifert TR, Su Z, Cox BF, Decker MW, Sullivan JP. ABT-089:
pharmacological properties of a neuronal nicotinic
acetylcholine receptor agonist for the potential treatment
of cognitive disorders. CNS Drug Rev . 2004 Jan 1 ;
10(2):167-82. Abstract
|
|
|
|
|
Text Size 
See our most recent Schizophrenia Bulletin theme Webinar: